Mutations in the cohesin complex in acute myeloid leukemia: Clinical and prognostic implications

Blood

Volumn 123, Issue 6, 2014, Pages 914-920

  Thol, Felicitas ^a   Bollin, Robin ^a   Gehlhaar, Marten ^a   Walter, Carolin ^b   Dugas, Martin ^b   Suchanek, Karl Josef ^a   Kirchner, Aylin ^a   Huang, Liu ^a,c   Chaturvedi, Anuhar ^a   Wichmann, Martin ^a   Wiehlmann, Lutz ^a   Shahswar, Rabia ^a   Damm, Frederik ^d   Göhring, Gudrun ^a   Schlegelberger, Brigitte ^a   Schlenk, Richard ^e   Döhner, Konstanze ^e   Döhner, Hartmut ^e   Krauter, Jürgen ^a,f   Ganser, Arnold ^a   Heuser, Michael ^a   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF SHANGHAI FOR SCIENCE AND TECHNOLOGY   (China)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COHESIN; PROTEIN RAD 21; PROTEIN SMC 1A; PROTEIN SMC 3; PROTEIN STAG 1; PROTEIN STAG 2; UNCLASSIFIED DRUG; BAALC PROTEIN, HUMAN; CELL CYCLE PROTEIN; CELL NUCLEUS ANTIGEN; NONHISTONE PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEOCHONDROITIN SULFATE; RAD21 PROTEIN, HUMAN; SMC3 PROTEIN, HUMAN; STAG1 PROTEIN, HUMAN; STAG2 PROTEIN, HUMAN; STRUCTURAL MAINTENANCE OF CHROMOSOME PROTEIN 1; TUMOR MARKER; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SOMATIC MUTATION; STOP CODON; WILD TYPE; CANCER STAGING; CASE CONTROL STUDY; CHROMOSOME ANALYSIS; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; REMISSION; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, NUCLEAR; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CHONDROITIN SULFATE PROTEOGLYCANS; CHROMOSOMAL PROTEINS, NON-HISTONE; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84897573903     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-518746     Document Type: Article

References (40)

1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
2. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
3. Remeseiro S, Losada A. Cohesin, a chromatin engagement ring. Curr Opin Cell Biol. 2013;25(1):63-71.
4. Wassmann K. Sister chromatid segregation in meiosis II: deprotection through phosphorylation. Cell Cycle. 2013;12(9):1352-1359.
5. Wendt KS, Yoshida K, Itoh T, et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature. 2008;451(7180):796-801. (Pubitemid 351253176)
6. Gerton JL. Translational mechanisms at work in the cohesinopathies. Nucleus. 2012;3(6):520-525.
7. Barber TD, McManus K, Yuen KW, et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA. 2008;105(9):3443-3448.
8. Schlenk RF, Döhner K, Krauter J, et al German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
9. Heil G, Krauter J, Raghavachar A, et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged
10. Mitelman F. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
11. Thol F, Damm F, Lüdeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889-2896.
12. Wagner K, Damm F, Göhring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010;28(14):2356-2364.
13. Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010;116(4):614-616.
14. Damm F, Oberacker T, Thol F, et al. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol. 2011;29(6):682-689.
15. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22(4):624-633. (Pubitemid 41095065)
16. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20(15):3254-3261. (Pubitemid 34831523)
17. Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010;28(4):578-585.
18. Baldus CD, Martus P, Burmeister T, et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol. 2007;25(24):3739-3745. (Pubitemid 47376607)
19. Marcucci G, Maharry K, Whitman SP, et al; Cancer and Leukemia Group B Study. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2007;25(22):3337-3343. (Pubitemid 47325620)
20. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WLJ, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003;101(3):837-845.
21. Damm F, Heuser M, Morgan M, et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood. 2011;117(17):4561-4568.
22. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006;108(12):3898-3905. (Pubitemid 44864574)
23. Heuser M, Argiropoulos B, Kuchenbauer F, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood. 2007;110(5):1639-1647. (Pubitemid 47443982)
24. Novocraft Technologies. NovoalignCS. Available at: www.novocraft.com. Accessed June 11, 2013.
25. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498.
26. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841-842.
27. Cheson BD, Bennett JM, Kopecky KJ, et al International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
28. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5(3):255-260.
29. Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639-1645.
30. Grimwade D, Walker H, Oliver F, et al The Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
31. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
32. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
33. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578-3584.
34. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636-3643.
35. Barbero JL. Genetic basis of cohesinopathies. Appl Clin Genet. 2013;6:15-23.
36. Lee BK, Iyer VR. Genome-wide studies of CCCTC-binding factor (CTCF) and cohesin provide insight into chromatin structure and regulation. J Biol Chem. 2012;287(37):30906-30913.
37. Zlatanova J, Caiafa P. CTCF and its protein partners: divide and rule? J Cell Sci. 2009;122(Pt 9):1275-1284.
38. Schmidt D, Schwalie PC, Ross-Innes CS, et al. A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res. 2010;20(5):578-588.
39. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090-1098.
40. Krönke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122(1):100-108.